Texas lawmakers want to add warning label to social media platforms

The Brief
A House Committee on Public Health hearing was held Monday to discuss House Bill 499, authored by Texas Rep. Mary Gonzalez (D-Clint).
The bill would require users to click on a warning label, stating they understand the association between social media use and a minor's significant mental health issues.
Last summer, then-U.S. Surgeon General Vivek Murthy made the same plea to Congress with a bill dubbed the Stop the Scroll Act. It was introduced in September but never made it out of committee.
Gonzalez said the bill would require the Health and Human Services Commission to write the warning with input from a panel of experts. The bill was left pending in the public health committee.
With growing data linking social media use to an increase in teen depression, eating disorders and suicides, Texas House lawmakers debated whether there should be warning labels placed on platforms.
The bill being debated would require platforms like Facebook, Instagram and TikTok to show a warning that there is a link between a teen's social media usage and significant mental health issues.
What we know
A House Committee on Public Health hearing was held Monday to discuss House Bill 499, authored by Texas Rep. Mary Gonzalez (D-Clint).
The bill would require users to click on a warning label, stating they understand the association between social media use and a minor's significant mental health issues.
Last summer, then-U.S. Surgeon General Vivek Murthy made the same plea to Congress with a bill dubbed the Stop the Scroll Act. It was introduced in September, but it never made it out of committee.
Rep. James Frank (R-Wichita Falls) wants a warning to include the addictive nature of social media.
"They have the data that shows how addictive it is," he said. "They have hired child psychologists to make sure it is more addictive and then withheld that information from parents."
Lawmakers also debated if a warning label would actually have an impact.
Gonzalez said the label would educate both teens and their parents.
What they're saying
"We know adolescents who spend more than three hours a day on social media face risks of anxiety and depression," said Gonzalez. "We know when we added cigarette health warning labels, the understanding of consumption raised for the consumer."
Dr. Lauren Gambill, a pediatrician representing the Texas Medical Association and the Texas Pediatric Society, said she's seen the damage from social media on her patients firsthand.
"As a hospital-based pediatrician, I take care of kids in the hospital following suicide attempts at an alarming frequency," she told the committee.
Gambill said in her decade of practice, problems linked to social media are not only becoming more frequent, but the children impacted are becoming younger. Problems extend beyond depression and suicide attempts to eating disorders prompted by so-called health influencers.
"My patients tell me they follow 'what I eat daily' trends and go to social media for grueling workout routines," she said. "By the time they get to me, they are so nutritionally depleted that their heartrates slow down, and they can't maintain their blood pressures."
Dr. Gambill told the committee the warning label would be a step in the right direction to address the ongoing mental health crisis.
"Will it solve it? Will it reach every child? Absolutely not," she said. "But I think if we save even one life, I think it would be important."
What's next
Gonzalez said the bill would require the Health and Human Services Commission to write the warning with input from a panel of experts.
The bill was left pending in the public health committee.
The Source
Information in this article comes from Monday's Texas House Committee on Public Health hearing, State Rep. Mary Gonzalez (D-Clint) and previous news coverage.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Vogue

7 hours ago

• Vogue

The 'Cortisol Cocktail' Isn't Just Delicious—It Also Works

We don't need data to confirm that we're stressed—but there are countless studies and polls out there doing it. Case in point: The most recent Censis-Eudaimon Report, which revealed that 31.8% of people feel close to burnout due to work stress. It makes sense that social media is filled with stress-busting remedies. And while some of them should fall into the realm of old wives' tales, others may just be legit. The most popular one right now? A viral drink recipie claiming to lower cortisol, restore energy, relieve tension, and balance hormones. Besides the catchy name—the Cortisol Cocktail—could it be real? We dive in (and drink up). TikTok content This content can also be viewed on the site it originates from. What is cortisol? First things first: Cortisol is a hormone produced by the adrenal glands in response to stress. Producing cortisol is typically a valuable ally for the body, as it plays a key role in regulating the metabolism, inflammation, and blood sugar levels, as well as having a direct influence on circadian rhythm. It's essential for the human body to survive, and because of that, the goal is never to eliminate it—but there is such a thing as too much cortisol. A consistently high level prevents your body from regaining homeostasis. Instead, you live in a place of constant stress. TikTok content This content can also be viewed on the site it originates from. The Cortisol Cocktail recipe 200 ml of coconut water ½ squeezed lemon 50 ml of orange juice 1 teaspoon of magnesium powder ¼ teaspoon fine salt Sparkling water to taste Why the Cortisol Cocktail works Each of the ingredients of the Cortisol Cocktail is carefully chosen for its health-supporting benefits: salt, magnesium, orange, and lemon. Alone, they are great—but combined? Well, that's why the drink has gone viral. Sodium, potassium, and sugars, in fact, represent the perfect cocktail to give the body a boost. The presence of coconut water, on the other hand, promotes hydration, as well as giving the drink a delicate and pleasant flavor. It's a nonalcoholic cocktail that allows you to imagine yourself elsewhere, on vacation perhaps, acting on the negative effects of cortisol and helping to relax the mind.

Business Upturn

11 hours ago

• Business Upturn

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

By GlobeNewswire Published on June 23, 2025, 00:35 IST New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors 1 . . Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk 1 . . FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system 2 . . These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3. Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. In the study, the first Mim8 maintenance dose was administered on the next planned emicizumab dosing day. Patients were given the option of switching to once-monthly, once every two weeks or once-weekly dosing frequencies of Mim8, regardless of their prior dosing frequency1,3. Steady-state Mim8 concentration was achieved by Week 16, and emicizumab elimination was completed by Week 261. Switching to Mim8 led to a sustained increase in thrombin peak levels without an exaggerated thrombin response1. 'Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with haemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period,' said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. 'This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease.' The open-label phase 3b FRONTIER5 study consisted of 61 adults and adolescents, aged 12 years and older, with haemophilia A. Mim8 was well-tolerated with no safety concerns. No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no clinical evidence of neutralising anti-Mim8 antibodies1. The PROs data from FRONTIER5 indicated a strong overall preference for the Mim8 pen-injector, with 97% (n=57/59) of patients reporting a 'very strong' or 'fairly strong' preference in comparison to their previous emicizumab injection system2. Of the participants who completed the Haemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector 'very easy' or 'easy' to use, and 95% (n=56/59) found it 'much easier' or 'easier' compared with their previous administration method. All participants (100%) were 'extremely confident' or 'very confident' in using the pen-injector correctly, and most participants (83%; n=49/59) found it 'very easy' to inject the dose2. 'The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with haemophilia A and demonstrate our continued commitment to developing innovative treatment options for this community', said Stephanie Seremetis, chief medical officer and CVP for Haemophilia at Novo Nordisk. 'These results give valuable insights into haemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device.' Novo Nordisk expects to submit Mim8 for regulatory review during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026. About haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding4. It is estimated to affect approximately 1,125,000 people worldwide5. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing4. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX4. Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe haemophilia A develop inhibitors6 that can cause replacement therapies to stop working. About Mim8 Mim8 is an investigational FVIIIa mimetic bispecific antibody optimised with the aim to deliver improved potency and sustained efficacy across flexible dosing intervals up to once-monthly prophylaxis for people living with haemophilia A, with or without inhibitors7-10. Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity into the normal range, helping blood to clot7,11. The use of Mim8 in people living with haemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trial FRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with haemophilia A, with or without inhibitors3. The FRONTIER clinical programme investigates Mim8 as a prophylaxis treatment for people with haemophilia A, with or without inhibitors. This programme includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER53,12-15. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Available at: Last accessed: June 2025. MedlinePlus. Hemophilia. Available at: Last accessed: June 2025. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. doi: 10.5045/br.2019.54.3.204. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. doi: 10.1182/blood.2020010331. Mancuso EM, et al. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study. Abstract presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress. Kenet G, et al. Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: phase 3 FRONTIER3 study. Abstract presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2025 Annual Congress. Session 6. Chowdary P, Banchev AM, Kavakli K, et al. Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study. Abstract presented at the American Society of Hematology (ASH) 2024 Annual Congress. Session: 322. U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Available at Last accessed: June 2025. A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1). Available at: Last accessed: June 2025. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Available at: Last accessed: June 2025. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Newsweek

16 hours ago

• Newsweek

Mom Gets Son To Sleep, Feels 'So Guilty' Over What She Sees on Baby Cam

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A mom-of-two found a genius way of getting her infant son to sleep, but when she checked in on his baby cam, what she saw left her heartbroken. Parenthood brings with it a myriad of challenges that change and evolve as children grow up. In the first few years at least, one of the biggest centers on sleep, or rather the lack of it. According to one 2019 study published in the journal Sleep, moms and dads can expect to experience some form of sleep deprivation for the first six years of their child's life. For those parents in the trenches of that developmental stage, exhaustion and frustration can set in when a child struggles to get the necessary rest. Louise Wright, from Nottinghamshire in the U.K, knows this only too well. She's a mom of two with 7-year-old and 4-month-old boys to contend with. Right now, it's the younger of her two sons who is proving problematic at bedtime. "He is 4 months old and in the 4-month sleep regression which is really tough, especially when I have another kid to settle," Wright said. "The days feel long when they don't nap and so you often count down until bedtime. It can be really frustrating pacing the room waiting for them to sleep then trying to transfer them into their cot." One night recently, Wright hit upon an idea to help her understandably clingy son get off to sleep when she put him down in his bed. "I decided to take off my T-shirt and put it beside him," Wright said. Aware that it wouldn't be safe for him to sleep the whole night through alongside the garment, Wright switched on her son's baby cam and moved to the other room where she would watch and wait until he was fast asleep. But then something unexpected happened. "As I watched him, I sat down for the first time that day and of course as a parent all the guilt begins to sneak in that you yelled too much or wished the time away," Wright said. "As I watched him snuffle up to my T-shirt and take comfort from it I felt so sad for rushing the bedtime process because all he needed was me, his mum." Eager to express the conflicting emotions she felt in that moment, Wright posted a clip of the baby cam footage to her TikTok, @lemon_squeezey, explaining how watching her son cuddle into the T-shirt left her feeling "so guilty." This feeling of guilt wasn't just focused solely on her younger son either. "My other boy is 7 and although he's independent and can do his own thing while he waits for me to settle his brother, it's not fair on him to miss out on time or to have a snappy irritable parent," Wright said. The video was met with a positive response though as other moms online sought to reassure her. "You're an amazing mum," one viewer wrote. "It's very valid to feel touched out and overstimulated but in the end of it all." Wright hopes the video reminds people how tough motherhood can be in these moments. "It's lonely being a mum and sometimes you can feel as though you are the only one in the depths of sleep deprivation," she said. Though she may have been struggling at that precise moment, the response this clip and many others like it, that she has shared online, has helped her realize she is not alone. "I've built a great community of mum friends," she said. One day her kids will both sleep soundly in their beds. Until then, Wright is determined to enjoy every moment she can.